A number of promising drugs in the pipeline can lower hepatitis B virus (HBV) DNA and antigen levels. Some may offer a functional cure for selected individuals, but agents that offer a reliable cure for most patients are not yet on the horizon. This would be expected to substantially reduce the likelihood of liver disease progression and the development of hepatocellular carcinoma, although the risk does not fall to zero.
